Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on August 26, 2020. The report addresses Item 8.01 (Other Events) regarding a corporate financing action.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notice of a capital raising event rather than a financial performance report.
Material Changes
On August 26, 2020, the Company entered into an Underwriting Agreement with H.C. Wainwright & Co., LLC. This agreement facilitates a registered public offering of the Company's common stock.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the offering. The terms of the offering are detailed in the press release filed as Exhibit 99.1, which is incorporated by reference.
Investor Verification Checklist
- Review the press release (Exhibit 99.1) for the specific number of shares offered and the offering price.
- Verify the total gross proceeds expected from the registered public offering.
- Confirm the use of proceeds as outlined in the Underwriting Agreement.
- Check for any lock-up agreements or underwriting discounts associated with the offering.